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Background/aim: Since the majority of the IgG4-related disease (IgG4-RD) patients in the literature are from the Far East and the
United States, there is a lack of large series from other parts of the world. We aimed to identify the clinical characteristics and outcome
of Turkish IgG4-RD patients from a tertiary center.
Materials and methods: Fifty-two patients classified as having definite IgG4-RD according to comprehensive diagnostic criteria were
included in the study. Patients not fulfilling the definite criteria due to lack of pathologic specimen and/or serum IgG4 levels were
excluded (n = 47). Clinical, laboratory, and histopathological features and treatment approaches were analyzed.
Results: Median age at diagnosis was 51.1 years and sex predominance was not observed (male/female: 26/26). Median follow-up
duration was 18 (IQR 25–75: 8–35) months. Retroperitoneal fibrosis was the most frequent presentation. Twenty-four (46.1%) patients
had localized involvement. Corticosteroids were the mainstay of treatment (92.5%). Rituximab had been used for cases resistant to
previous treatment or with relapses in 19 (47.5%) patients. A complete response was achieved in 52.5% and partial response (<50%
regression) in 40%.
Conclusion: This large and first cohort of IgG4-RD patients from Turkey showed similar clinical features to European cohorts, except
for the male predominance in previous cohorts. Corticosteroids and rituximab are effective in IgG4-RD but there is still uncertainty
about the usage of corticosteroid-sparing agents.
Key words: IgG4-related disease, retroperitoneal fibrosis, coronary periarteritis, corticosteroids, immunosuppressive agents, rituximab

1. Introduction
IgG4-related disease (IgG4-RD) is an emerging immunemediated disease with the capability of involving essentially
any organ (1). It was firstly described in the first years of
the 21st century and the name of IgG4-RD was proposed
in 2012 by an international multidisciplinary study group
(2). Clarification of the pathophysiology and diagnostic
criteria is ongoing. Despite the majority of patients
reported in the literature to date being from the Far East
and the United States, the condition has been described
all across the world (2–4). There are a few publications
describing the European and Middle Eastern experience of
IgG4-RD (5–8). In recent years some observational studies
were published from Spain, France, and Italy (9–11). There
is still a lack of large series from other parts of the world.
* Correspondence: drsameterden@gmail.com

The frequencies of clinical features in IgG4-RD have
been different among pancreatobiliary series, glandular
series, and systemic series (2). In a newly published review
of six cohorts, the main organs involved were diverse due
to the different inclusion and diagnostic criteria used
for the different cohorts (12). The prevalence of specific
organ involvement varied widely between studies and is
principally influenced by the nature of patient collection
(unselected or selected by organ).
Serum IgG4 concentrations are often considered
useful, albeit with some limitations. Approximately 30% of
IgG4-RD patients have normal serum IgG4 concentrations
despite classic histopathological and immunohistochemical
findings (1). Moreover, false positive results could be seen
in chronic sinusitis, tuberculosis, and malignancy (7).
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Multiple approaches to the management of IgG4-RD
have been reported, including surgical resection of affected
tissues and treatment with systemic glucocorticoids,
“steroid-sparing” immunosuppressive drugs, or biologic
agents (13). However, no formal treatment guidelines
exist (14). Although corticosteroids are the mainstay of
treatment, up to 40% of patients relapse within the first
year. More data are required to elucidate the dosing
of corticosteroids and possible coadministration of
immunosuppressives/biologic agents.
This study aimed to identify the clinical characteristics,
treatments, and outcomes of Turkish patients from a
tertiary center with IgG4-RD.
2. Materials and methods
The institutional ethics committee of Hacettepe University
approved the study. Patients were diagnosed with IgG4RD according to comprehensive diagnostic criteria
(15): (a) clinical/radiological examination showing
characteristic diffuse or localized swelling or masses in
single or multiple organs; (b) hematological examination
showing elevated serum IgG4 concentrations (>135 mg/
dL); (c) histopathological examination showing (i) marked
lymphocyte and plasmacyte infiltration, (ii) storiform
fibrosis, and (iii) infiltration of IgG4+ plasma cells with
a ratio of IgG4+/IgG+ plasma cells of ≥40% and a total
of ≥10 IgG4+ plasma cells per high-power field. The

diagnosis of IgG4-RD was definitive in patients with
a+b+c. Correspondingly, patients were diagnosed with
IgG4-RD if they had organ-specific criteria for IgG4related autoimmune pancreatitis, IgG4-related Mikulicz’s
disease, and IgG4-related kidney disease.
Patients’ data were acquired via 2 sources (Figure 1):
first, the database of our rheumatology center between
May 2007 and October 2012 was screened for patients
having any disease under the clinical spectrum of IgG4RD (retroperitoneal fibrosis (RPF), inflammatory
pseudotumor,
eosinophilic
angiocentric
fibrosis,
periaortitis, pancreatitis, sialoadenitis, mediastinal fibrosis,
Mikulicz’s syndrome). Hospital charts of 70 patients were
retrospectively analyzed and clinical, histopathology, and
laboratory features including serum IgG4 levels were
reviewed. Sixteen patients were excluded due to the absence
of histopathologic specimens. Pathologic specimens of 54
patients were reevaluated in terms of IgG4-RD. Moreover,
37 patients did not met the definite diagnostic criteria. At
the end of the first step, 17 patients were included in the
study.
In the second step, patients with an existing diagnosis
of IgG4-RD between October 2012 and September 2016
were evaluated (Figure 1). Ten patients were excluded due
to not fulfilling definite diagnostic criteria. Thirty-five
patients were enrolled in the study from the second step.
A standardized dataset including demographic data,

Figure 1. Flowchart of the patients’ enrollment and data analysis of the study.
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clinical characteristics, and imaging and laboratory
findings of IgG4-RD was set up and completed for each
patient.
Systemic disease was defined by the presence of 2
or more affected organs. Those with less than 2 organs
affected were considered as localized cases.
2.1. Hematological and serological assessments
All patients’ laboratory data were noted, including complete
blood counts, liver and renal function assessment, and
serological testing including acute phase reactants (APRs),
C-reactive protein, erythrocyte sedimentation rate, and
complement levels. Antinuclear antibodies (ANAs),
extractable nuclear antigens (ENAs), antineutrophil
cytoplasmic antibodies (ANCAs), and serum IgG4
levels were measured at the time of first presentation by
nephelometric methods at Düzen Laboratory Group,
Ankara, Turkey, or the Hacettepe University Hospital
laboratories and a level of >135 mg/dL was considered as
elevated, while >405 mg/dL was very high (13). Increased
APR level was accepted as an erythrocyte sedimentation
rate of >30 mm/h or C-reactive protein level of >10 mg/L.
2.2. Follow-up, therapeutic strategies, and outcomes
The use of corticosteroids, immunosuppressive agents,
and biologic therapies as well as previous radical or
palliative surgery was noted. Adjuvant therapies such as
radiotherapy were also recorded.
Treatment response was evaluated after 3–6 months
and was assessed according to 3 outcome groups: complete
(complete regression of the fibrotic mass/masses and
systemic symptoms), partial (<50% of regression of the
mass/masses and cessation of the systemic symptoms),
and none.
During follow-up, the number and causes of death
were recorded.
2.3. Statistical analysis
Statistical analysis was performed with SPSS 15.0 (SPSS
Inc., Chicago, IL, USA). Descriptive statistics included
mean (standard deviation, SD) and median (25th–75th
quartiles). Comparisons between categorical variables
were performed using chi-square tests. Correlation
analysis was done with Pearson or Spearman correlation
tests according to the distribution of the variables.
3. Results
3.1. Patients’ characteristics and organ involvement
In total, 52 patients (26 males) were recruited into the
study. All patients met the criteria for a “definite” diagnosis
of IgG4-RD. Mean (±SD) age at diagnosis was 51.1 ± 12.7
years. A history of atopy/allergy was present in 9 (17.3%)
patients.
The presence of previous autoimmune disease was
seen in 10 (19.2%) patients: 3 had Hashimoto’s thyroiditis,

two had Graves’ disease, and a previous history of systemic
sclerosis, rheumatoid arthritis, vitiligo, psoriatic arthritis,
or psoriasis was respectively noted in 5 other patients.
The clinical spectrum of the patients was broad, with
the involvement of different anatomical sites for protean
manifestations. RPF was the most frequent feature.
Pancreatitis, periorbital lesions, salivary gland involvement,
cardiovascular involvement, and constitutional symptoms
were present in approximately one-fourth of patients.
Lymphadenopathy was found in 20 (39.2%) patients and
was observed alongside other common presentations
as well as being the initial manifestation of the disease.
Lymphadenopathy in the cervical, supraclavicular,
mediastinal, hilar, and intraabdominal regions was
observed. The distribution of different organs involved
and the frequencies are shown in the Table. In contrast
to other rheumatic diseases, no patients had arthritis/
enthesopathy or deep vein thrombosis and arthralgia was
seen in 11 (27.5%) of patients.
Twenty-four (46.1%) patients had localized
involvement. Distribution according to organ involvement
included RPF (n = 13), pancreatitis (n = 3), mediastinal
fibrosis (n = 2), nasopharyngeal pseudotumor (n =
1), eosinophilic angiocentric fibrosclerosis (n = 1),
dacryoadenitis (n = 1), kidney involvement (n = 1),
pachymeningitis (n = 1), and orbital pseudotumor (n = 1).
No difference was found between male and female
patients regarding clinical features, except for RPF (73.0%
vs. 27.0%, P = 0.001).
Median serum IgG4 level was 280 (IQR 25–75 :
98.5–642) mg/dL. Distribution of serum IgG4 levels were
normal in 32.7%, elevated in 46.1%, and very high in 21.2%
of cases. None of the localized cases had very high IgG4
levels (>405 mg/dL). Increased APR at first diagnosis was
found in 32 (61.5%) of patients. No correlation was found
between acute phase reactants and serum IgG4 levels (P
> 0.05). Moreover, the number of organ systems involved
was not related to an increase in acute phase reactants (P
> 0.05).
Seven patients had an ANA titer of ≥1/160, but none
of them had ENA positivity. MPO-ANCA was found in
one patient. Hypocomplementemia was not seen in any of
patients.
3.2. Follow-up, therapeutic strategies, and outcomes
Twelve patients had missing data regarding follow-up and
treatment. Subsequently, analysis was performed with 40
patients.
Surgical resection was performed in 10 (25%) patients
as a diagnostic/therapeutic process and all were done
before IgG4-RD was diagnosed. Eight had RPF-related
surgery (including ureteral stent insertion) and two
required surgery for periorbital lesions. Only 3 (7.5%)
patients underwent surgery alone and were not treated;
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Table. Distribution of clinical findings and organ involvement
(n = 52).
Constitutional symptoms
· Fatigue
· Tiredness
· Night sweats
· Weight loss
· Fever

· 31 (59.6%)
· 16 (30.7%)
· 15 (28.8%)
· 14 (26.9%)
· 13 (25%)

Retroperitoneal fibrosis

23 (44.2%)

Lymphadenopathy

20 (39.2%)

Any cardiovascular involvement
· Periaortitis
· Pericardium
· Coronary periarteritis
· Abdominal aorta aneurysm

15 (28.8%)
· 12 (23.1%)
· 5 (9.6%)
· 4 (7.7%)
· 1 (1.9%)

Orbital pseudotumor
· Orbital mass/proptosis
· Extraocular muscles

12 (23.1%)
· 6 (11.5%)
· 6 (11.5%)

Pancreas

12 (23.1%)

Major salivary glands

11 (21.2%)

Lacrimal glands

9 (17.3%)

Mediastinal fibrosis

6 (11.5%)

Ear, nose, sinuses

5 (9.6%)

Lung fibrosis

5 (9.6%)

Skin

4 (7.7%)

Pleura

4 (7.7%)

Gall bladder and biliary ducts

4 (7.7%)

Thyroid

3 (5.8%)

Liver

3 (5.8%)

Kidneys (mass)

3 (5.8%)

Pachymeningitis

2 (3.8%)

Breast involvement

1 (1.9%)

Tubulointerstitial nephritis

1 (1.9%)

one of them was a totally resected kidney-involved patient,
while one with cervical lymphadenopathy and one with
RPF was surgically treated. Later two patients progressed
and medical therapy was started (Figure 2).
The initial therapeutic approach in all treated patients
(n = 37) was the administration of glucocorticoids (GCs).
Pulse methylprednisolone was used for 1–3 days according
to severity in patients with pachymeningitis (n = 2), orbital
pseudotumor (n = 3), periaortitis (n = 3), mediastinal
fibrosis (n = 3), and coronary periarteritis (n = 4). Oral
prednisolone was started at a daily dose of 0.5–0.6 mg/
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kg in patients with localized involvement and 1 mg/kg in
patients with multiorgan involvement. GCs were gradually
tapered over a period of 6 months. Six (42.8%) patients
responded to treatment, but 3 of them relapsed during
dose reduction. Rituximab was used in 9 of these patients
because of resistance and/or adverse effects (Figure 2).
The combination of GCs with immunosuppressive
agents (methotrexate (MTX) 10–20 mg/ week or
azathioprine (AZA) 2–3 mg/kg per day or pulse
cyclophosphamide (CYC) 500 mg 2–4 weeks apart, total
dose less than 6 g) was used as first-line induction therapy
in 23 (57.5%) patients. Eight patients responded well to
the GC+MTX/AZA combination (Figure 2). Even though
patients on GC+CYC responded well, relapse was seen
frequently in this group. Four patients were switched to
rituximab.
Rituximab (1 g twice 2 weeks apart) was used as a
second-line treatment for patients resistant to previous
treatments or relapsed patients. Nineteen (47.5%) patients
had used rituximab (Figure 2). In 10 of these patients,
rituximab was given once more (2 g). In two of these
patients, two additional courses of rituximab (1 g) were
used because of lack of response. No relapse was observed
after rituximab treatment.
No difference was found regarding treatment between
patients with systemic and localized disease (P = 0.456).
Local radiotherapy was used as adjunctive therapy in
a patient with eosinophilic angiocentric fibrosis. However,
it was unsuccessful and this patient was switched to
rituximab.
Thirteen subjects (32.5%) presented relapses. No
statistical difference was found regarding tendency to
flare between systemic and localized IgG4-RD forms (P =
0.901).
Twenty-one (52.5%) patients achieved a complete
response and 16 (40%) presented a partial response (<50%
of regression) after a median of 18(IQR 25–75: 8–35)
months of follow-up. One patient with RPF and coronary
periarteritis failed to respond to all treatments including
prednisolone, cyclophosphamide, and rituximab.
Eventually, coronary artery by-pass graft was performed
due to persistent angina pectoris. No difference was
found between systemic and localized patients regarding
complete/partial response rates (P = 0.513).
Within the 14 subjects who started prednisone only, 4
had complete resolution and 1 had partial resolution with
only prednisolone. Among the patients who used GC in
combination with any other immunosuppressive agent as
first-line treatment, five had complete response and six
had a partial response.
In total, 3 patients died during this period. Two of the
deaths were attributed to IgG4-RD: cardiac failure due to
constrictive pericarditis (n = 1) and pulmonary failure due
to mediastinal fibrosis (n = 1). A patient with pancreatitis
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Figure 2. Treatment flowchart of IgG4-RD patients (n = 40).

died due to myocardial infarction 5 years after the first
diagnosis and this was not thought to be related to IgG4RD.
One patient had previous acute lymphoblastic
leukemia (ALL) 20 years before the diagnosis of IgG4-RD.
No malignancy was observed during follow-up.
4. Discussion
In this single-center observational study, we aimed to
describe the clinical features of 52 Turkish patients with
IgG4-RD together with the treatments and outcomes.
Middle-aged individuals were the most affected, in
line with previous studies. No sex predominance was
observed. The clinical features observed were similar to
those previously described from European cohorts. Nearly
half of the patients had localized disease. Even though
additional immunosuppressive agents were used in more
than half of the patients, treatments had to be switched to
rituximab in a subgroup. Most patients had an acceptable
response. Two deaths were directly related to the disease
and we observed no malignancy during follow-up.

IgG4-RD is characterized by the involvement of
multiple organ systems. The pancreas is frequently
involved. Autoimmune pancreatitis has been reported in
approximately 50% of cases (2). Other studies reported
the predominance of involvement of salivary glands and
lymphadenopathy in American and Chinese cohorts,
whereas a Spanish cohort was characterized by the
predominance of RPF and orbital pseudotumor. According
to an Italian cohort, the predominance of pancreatic
involvement and RPF was seen (2,12). In our cohort,
RPF was the most frequent presentation; other common
features were, in descending order, lymphadenopathy,
orbital pseudotumor, pancreatitis, and salivary gland
involvement. Few cases of tubulointerstitial nephritis
or biliary involvement were observed. The incidence of
localized IgG4-RD (46.1%) in our series is similar to that
reported by previous studies (ranging between 22% and
59%).
Cardiovascular involvement may be manifested
as cardiac pseudotumors, inflammatory periaortitis,
coronary arteritis, and/or pericarditis (16). IgG4-related
cardiovascular disorders can severely affect prognosis.
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Panarteritis in a coronary artery of a patient with RPF was
initially described in 1966 (17). There are few cases of IgG4related coronary periarteritis (17–20). Delayed diagnosis
can result in development of giant aneurisms, as in a
patient of our cohort. Inflammatory pericarditis leading
to constrictive pericarditis can be fatal, as described in
one patient in our cohort (18). Physicians should be aware
of the importance and mortality potential of coronary
periarteritis/inflammatory pericarditis in IgG4-RD.
We did not find any malignancy related to IgG4-RD,
except for one case of ALL, which had been diagnosed
20 years previously. No malignancy was reported during
follow-up. We did not observe a link between IgG4RD and neoplasms. Concomitant lymphadenopathy is
often found in patients with IgG4-RD. More than onethird of our patients had lymphadenopathy, which is
line with previous studies. Lymph nodes in cervical,
supraclavicular, mediastinal, hilar, and intraabdominal
areas have been involved. Lymphadenopathy sometimes
represents the initial manifestation of the disease, but it
is usually discovered by imaging of patients with known
IgG4-RD (21). When the lymphadenopathy is generalized,
the differential diagnosis includes lymphoma, Castleman’s
disease, and disseminated malignancy. Even though
previous reports mentioned no fever or weight loss in
IgG4-RD, one-third of our patients had constitutional
symptoms and weight loss was reported in 14 patients.
Constitutional symptoms in addition to generalized
lymphadenopathy can be seen in malignancy and IgG4RD. Exclusion of an underlying malignancy is therefore
paramount.
Our patients had a similar age at diagnosis and no
sex predominance was noted in comparison to previous
studies (2,12). In a few previous reports, patients with
IgG4-RD had increased allergic features such as atopy and
asthma (1). However, atopy/asthma was not found in the
majority of subjects and the prevalence was similar to that
expected in the general adult Turkish population (22). Sex
predominance in IgG4-RD studies is mainly influenced by
the major organ involvements seen in a given study (2,12).
There was a male predominance in a pancreatobiliary series
but in a glandular series no sex difference was reported in
the pooled analysis of Brito-Zeron et al. (2). Inoue et al.
reported that males presented with more periaortitis/RPF
(23). In our cohort RPF was three times more frequent
in males, but even for that there were no sex differences
observed regarding all IgG4-RD patients. There could be
slight differences related to organ involvement between
males and females (12,23). Sex predominance would be
better projected in further pooled international analysis
with different clinical presentations.
In most of the IgG4-RD studies, patients were included
using the comprehensive diagnostic criteria or 2012
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consensus criteria (15,24). We used the former criteria
and included only “definite” IgG4-RD patients. Some of
our patients were diagnosed using organ-specific criteria.
The comparison of these criteria has not been evaluated in
this study. The International Consensus criteria are based
on pathological findings, leaving IgG4 serum elevation
as a complementary finding (24). Thirty percent of our
patients had serum IgG4 levels within the normal range,
as in previous studies (12). On the other hand, increased
IgG4 levels might raise suspicion of systemic involvement.
Carruthers et al. reported a mean level of 405 mg/dL
associated with systemic involvement (13). None of the
localized cases had serum IgG4 levels higher than 405 mg/
dL. Serum IgG4 levels could be useful not only for diagnosis
but also as an important clue especially at much higher
levels.
Even though increased APRs are useful in the
monitoring of many rheumatic diseases, there is no
consensus for the use of APR in IgG4-RD. As in our study,
about 30% of patients have APRs within the normal range
(1,2). Moreover, the number of organ systems involved
is not related to an increase in APRs. APRs do not have
informative roles in IgG4-RD, as mentioned in the recent
International Consensus guidelines (14).
First-line therapy for IgG4-RD is corticosteroids.
However, there is a subgroup in which corticosteroid
monotherapy results in an incomplete response or high
relapse rate (12). Nonresponders were more likely receiving
glucocorticoid-sparing agents and/or rituximab. Steroid
nonresponders were more likely receiving glucocorticoidsparing agents in a range of 34.5%–60%. In our series, more
than 90% of patients had used corticosteroids. In contrast
to previous studies, more than half of our patients had been
on additional agents as first-line treatment. Although our
patients did not follow any previously defined treatment
regime, we observed a slightly lower relapse rate (32.5%)
compared to previous cohorts (24%–63%).
There is very little evidence about the clinical utility
of corticosteroid-sparing medications. Wallace et al.
demonstrated that all patients treated in their cohort with
steroid-sparing agents discontinued them due to lack of
response (4). The fibrotic components that occur in the later
phase of the disease could prevent the drugs interfering
with the inflammatory chain (12). Because of the small
patient numbers and no homogeneous evaluation of disease
activity index, further analysis could not be done. However,
early use of these agents might be a rational approach to
obtain better response with lower relapse rates even though
they have not been studied in a controlled or prospective
manner.
Rituximab has been described as a highly effective
treatment in IgG4-RD when combined (or not) with
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steroids (14,25). Half of our patients used rituximab due
to resistance to previous drugs or relapse. Moreover, no
relapse was observed. B-cell depletion achieves its effects
at least in part by interfering with the repletion of shortlived plasma cells that are producing IgG4. Rituximab
appears to be an important and well-tolerated alternative
agent for patients who do not respond to corticosteroids
and/or corticosteroid-sparing agents (14).
Most of our patients had an acceptable response.
Response rates differ between previous studies due
to heterogeneous evaluation methods. However, the
majority of patients had complete or partial responses in
all of the studies.
Limitations of our study arise from the inclusion of
retrospective cases, absence of standardized treatment
protocols, and lack of use of a disease activity index.
However, our data give an illustration of IgG4-RD in
Turkey in comparison to other cohorts. There is no
outcome measurement tool validated for IgG4-RD, but a
prototype activity index was proposed in 2012 (26). We
used a semiquantitative response index, also used in the
Spanish cohort (10). Using a disease activity index like an
‘IgG4-RD responder index’ might be useful in assessing

disease activity and damage and also in treatment efficacy.
In conclusion, we have described the largest series of
patients with IgG4-RD from Turkey. These patients had a
preponderance of disease involving the retroperitoneum,
salivary glands, and periorbital region. Overall, there was
a good response to treatment and corticosteroid-sparing
agents might be useful, especially in the early phase of the
disease. The introduction of rituximab may be the start
a new treatment era. Malignancy and mortality were
infrequent. Our work provides additional insights into
the clinical characteristics, natural history, and response
to treatment of IgG4-RD in a European population.
International collaborative studies and randomized
clinical trials will help in clarifying these areas of
uncertainty.
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